+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of aggressive primary lymphomas of the digestive system by intensive chemotherapy. Experience of the Study Group on Lymphomas in Adults with the LNH-84 protocol

Treatment of aggressive primary lymphomas of the digestive system by intensive chemotherapy. Experience of the Study Group on Lymphomas in Adults with the LNH-84 protocol

Annales de Gastroenterologie et D'hepatologie 28(4): 205-208

Ninety-one patients with primary gastrointestinal lymphoma included in the LNH-84 multicentric regimen were analyzed to determine the efficacy and the toxicity of intensive combination chemotherapy and of surgical debulking. All these patients had aggressive histological subtypes: 56 patients had localize disease, stage IE or IIE, and 35 patients had stage IV disease; 40 patients had bulky disease. Specific sites included stomach (43 cases), small bowel (35), ileo-cecum (13), colon (10), and rectum (6). Although 71 patients (78%) had an attempted surgical resection, only 28 (31%) had complete tumor excision. Patients were treated with 3 or 4 cycles of ACVB chemotherapy followed by sequential consolidation. Nine patients died during chemotherapy. With a median follow-up of 3 years, 10 patients have relapsed and predicted 4-year survival of the entire group is 62%. In stage IE or IIE patients, survival and disease-free survival are similar in patients who underwent complete resection or incomplete or no surgical resection prior to the administration of chemotherapy. Prognostic factors predicting for survival were similar to the entire group of patients treated with the LNH-84 regimen. Aggressive gastrointestinal lymphoma patients treated with intensive chemotherapy have outcome and prognostic factors comparable to those of other similarly staged aggressive lymphoma patients. Surgical resection prior to the administration of combination chemotherapy did not influence survival or disease-free survival in patients with localized disease.

(PDF emailed within 1 workday: $29.90)

Accession: 041850054

Download citation: RISBibTeXText

PMID: 1280028

Related references

Prognosis and treatment of malignant digestive lymphomas. II. Primary malignant lymphomas of the digestive tract in adults have special characteristics. Laparotomy retains a place in the diagnosis and treatment. Gastroenterologie Clinique et Biologique 8(5): 432-435, 1984

Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80). Journal of Clinical Oncology 4(2): 147-153, 1986

Prognosis and treatment of malignant digestive lymphomas. I. Primary lymphomas of the digestive tract should be treated like other malignant non-Hodgkin's lymphomas. Systematic laparotomy is not indispensable. Gastroenterologie Clinique et Biologique 8(5): 430-431, 1984

Alternating chemotherapy does not improve results in poor prognosis aggressive lymphomas LNH87 protocol group 3 A GELA study. Blood 82(10 SUPPL 1): 136A, 1993

Must low-burden aggressive lymphomas be treated with intensive chemotherapy? (LNH-87, Group 1). Pathologie-Biologie 41(1): 96-96, 1993

Intensive chemotherapy in aggressive lymphomas update results of lnh 80 protocol and prognostic factors affecting response and survival. Blood 70(5): 1394-1399, 1987

Intensive treatment of stage III-IV aggressive malignant lymphomas (protocol TPL-84). Haematologica 76(6): 479-484, 1991

Treatment of B-cell lymphomas in children and adults with a short duration intensive protocol. Anticancer Research 19(3A): 2028-2029, May-June, 1999

Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas. Annals of Hematology 82(8): 481-486, 2003

Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. Journal of Clinical Oncology 21(2): 266-272, 2003

Interim analysis of LSG-4 protocol study on the treatment of aggressive non-Hodgkins lymphomas in Japan. Kimura, K , Yamada, K , Carter, S K , Longo, D L International Congress Series; Cancer chemotherapy: Challenges for the future, Vol 8 : 289-294, 1993

An intensive 7 drug chemotherapy for diffuse aggressive lymphomas. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 1): 608, 1990

Initial experience of treatment of primary intraocular lymphomas associated with primary CNS lymphomas. Zhurnal Voprosy Neirokhirurgii Imeni N. N. Burdenko 76(4): 19-25; Discussion 25, 2013

Treatment of primary cerebral lymphomas with an intensive combination chemotherapy regimen without radiotherapy. Annals of Hematology 77(SUPPL 2): S67, 1998

The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. British Journal of Dermatology 157(6): 1205-1211, 2007